To decide Recommended dose of XELIRI and bevacizumab in patients with metastatic colorectal cancer who have oxlplatin based first-line chemotherapy including treatment failure or refractory, and To evaluate the safety and efficacy -PhaseI/II Study

Trial Profile

To decide Recommended dose of XELIRI and bevacizumab in patients with metastatic colorectal cancer who have oxlplatin based first-line chemotherapy including treatment failure or refractory, and To evaluate the safety and efficacy -PhaseI/II Study

Completed
Phase of Trial: Phase I/II

Latest Information Update: 01 Jul 2017

At a glance

  • Drugs Bevacizumab (Primary) ; Capecitabine (Primary) ; Irinotecan (Primary)
  • Indications Colorectal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 01 Jul 2017 Results published in the Cancer Chemotherapy and Pharmacology
    • 24 Jun 2017 Status changed from active, no longer recruiting to completed.
    • 04 Feb 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top